Haber, P.
2003  results:
Search for persons X
?
1

P294 Colorectal cancer screening in cystic fibrosis, what c..:

Taylor, N. ; Sivam, S. ; Halim, J....
Journal of Cystic Fibrosis.  22 (2023)  - p. S155 , 2023
 
?
2

ELX/TEZ/IVA use in cystic fibrosis liver disease: Is the pe..:

Gardiner, A. ; Volovets, A. ; Haber, P....
Journal of Cystic Fibrosis.  21 (2022)  5 - p. 881-884 , 2022
 
?
 
?
5

Relative bioavailability of 13C5-folic acid in pectin-coate..:

de Ambrosis, A ; Vishnumohan, S ; Paterson, J..
European Journal of Clinical Nutrition.  71 (2016)  1 - p. 103-106 , 2016
 
?
 
?
8

Post-Licensure Surveillance of Trivalent Live-Attenuated In..:

Haber, P. ; Moro, P. L. ; Cano, M....
Journal of the Pediatric Infectious Diseases Society.  4 (2014)  1 - p. 82-83 , 2014
 
?
10

Postlicensure Safety Surveillance for High-Dose Trivalent I..:

Moro, P. L. ; Arana, J. ; Cano, M....
Clinical Infectious Diseases.  54 (2012)  11 - p. 1608-1614 , 2012
 
?
 
?
13

Factors associated with uptake of treatment for recent hepa..:

Grebely, J. ; Petoumenos, K. ; Matthews, G.V....
Drug and Alcohol Dependence.  107 (2010)  2-3 - p. 244-249 , 2010
 
?
14

Characteristics and Treatment Outcomes among HIV-Infected I..:

Matthews, G. V. ; Hellard, M. ; Haber, P....
Clinical Infectious Diseases.  48 (2009)  5 - p. 650-658 , 2009
 
?
15

Characteristics and Treatment Outcomes among HIV‐Infected I..:

Matthews, G. V. ; Hellard, M. ; Haber, P....
Clinical Infectious Diseases.  48 (2009)  5 - p. 650-658 , 2009
 
1-15